Gietelink L, Wouters M W J M, Marijnen C A M, van Groningen J, van Leersum N, Beets-Tan R G H, Tollenaar R A E M, Tanis P J
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, The Netherlands; Scientific Board, Dutch Institute of Clinical Auditing, Leiden, The Netherlands.
Eur J Surg Oncol. 2017 Jul;43(7):1297-1303. doi: 10.1016/j.ejso.2016.12.019. Epub 2017 Mar 10.
BACKGROUND: The rate of preoperative radiotherapy (RT) for rectal cancer in the Netherlands has been the highest among European countries. Revision of the national guideline on colorectal cancer, officially published in 2014, specifically focussed on the indication for RT and MRI criteria to evaluate mesorectal lymph nodes. The objective of this study was to evaluate implementation of the revised guideline using a national audit. METHODS: Data of the Dutch Surgical Colorectal Audit (DSCA) between 2009 and 2014 were used to evaluate RT use and RT regimen for relevant subgroups of cM0 rectal cancer patients, as well as accuracy of pre-operative MRI. RESULTS: 14,018 patients were included for analysis. Overall RT use in cT1-4N0-2M0 stage ranged from 81.4% to 84.2% between 2009 and 2013, and decreased to 64.4% in 2014. The absolute decrease in RT use from 2013 to 2014 for cT1N0, cT2N0 and cT3N0 stage was 32.8%, 43.5% and 31.6%, respectively. Short course RT with delayed surgery was used as an alternative to chemoradiotherapy up to 2013 in 30.6% of patients over 80 years, and in 12.1% of patients with an ASA score >2; these percentages increased to 45.8% and 19.9% in 2014, respectively. Specificity of MRI for N-stage decreased from 82.9% in 2009 to 62.9% in 2013, with an increase to 73.2% in 2014. CONCLUSION: The revised national guideline on colorectal cancer was rapidly implemented in the Netherlands with a substantial decrease in RT use for low risk resectable rectal cancer, and increased specificity of MRI for N-staging.
背景:在欧洲国家中,荷兰直肠癌术前放疗(RT)的比例一直是最高的。2014年正式发布的国家结直肠癌指南修订版特别关注了放疗指征以及评估直肠系膜淋巴结的MRI标准。本研究的目的是通过全国性审计来评估修订后指南的实施情况。 方法:使用2009年至2014年荷兰结直肠外科审计(DSCA)的数据,评估cM0直肠癌患者相关亚组的放疗使用情况和放疗方案,以及术前MRI的准确性。 结果:纳入14018例患者进行分析。2009年至2013年,cT1-4N0-2M0期患者的总体放疗使用率在81.4%至84.2%之间,2014年降至64.4%。2013年至2014年,cT1N0、cT2N0和cT3N0期放疗使用率的绝对下降率分别为32.8%、43.5%和31.6%。截至2013年,80岁以上患者中有30.6%、美国麻醉医师协会(ASA)评分>2的患者中有12.1%使用短程放疗加延迟手术作为放化疗的替代方案;2014年,这些比例分别增至45.8%和19.9%。MRI对N分期的特异性从2009年的82.9%降至2013年的62.9%,2014年增至73.2%。 结论:荷兰迅速实施了修订后的国家结直肠癌指南,低风险可切除直肠癌的放疗使用率大幅下降,MRI对N分期的特异性提高。
Eur J Surg Oncol. 2013-6-28
Expert Rev Anticancer Ther. 2009-4
Eur J Surg Oncol. 2018-12-12
Br J Surg. 2020-9
Strahlenther Onkol. 2009-8
Eur J Surg Oncol. 2010-1-13
Int J Colorectal Dis. 2024-1-6
Cancers (Basel). 2023-2-10
J Surg Oncol. 2020-11
Int J Colorectal Dis. 2019-11-27